SCHEMBL30980689

SCHEMBL30980689

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1c1ccn(CCOCCOCCN)n1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 1/20 0.41
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MMP12 P39900 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980721 0.85 LGALS3 (0.49) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL30980633 0.84 LGALS3 (0.38) LGALS3CA1CA2CA9MAPK1
SCHEMBL30980768 0.79 LGALS3 (0.35) LGALS3
SCHEMBL30980728 0.76 LGALS3 (0.54) LGALS3CA1CA2CA9MAPK1
SCHEMBL24822648 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL24531188 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL10261426 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL23618308 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL2292636 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1
SCHEMBL730739 0.72 MAPK1 (0.65) LGALS3CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback